In Vitro and in Vivo Cytotoxic Effects of PRIMA-1 on Hepatocellular Carcinoma Cells Expressing Mutant P53ser249
Overview
Authors
Affiliations
Hepatocellular carcinoma (HCC) is highly lethal due to limited curative options. In high-incidence regions, such as parts of Africa and Southeastern Asia, >50% of cases carry an AGG to AGT mutation at codon 249 of the TP53 gene, considered as a 'signature' of mutagenesis by aflatoxins. The protein product, p53ser249, may represent a therapeutic target for HCC. The small molecule p53 reactivation and induction of massive apoptosis (PRIMA)-1 has been shown to induce apoptosis in tumour cells by reactivating the transactivation capacity of some p53 mutants. In this study, we have investigated the cytotoxic effects of PRIMA-1 on HCC cells expressing p53ser249. In p53-null Hep3B cells, over-expression of p53ser249 or p53gln248 by stable transfection increased the cytotoxicity of PRIMA-1 at 50 muM. Furthermore, PRIMA-1 treatment delayed the growth of p53ser249-expressing Hep3B cells xenografted in severe combined immunodeficiency mice. However, PRIMA-1 did not restore wild-type DNA binding and transactivation activities to p53ser249 or to p53gln248 in Hep3B cells. Moreover, in PLC/PRF/5, a HCC cell line constitutively expressing p53ser249, small interfering RNA (siRNA) silencing of the mutant increased the cytotoxic effect of PRIMA-1. These apparently contradictory effects can be reconciled by proposing that p53ser249 exerts a gain-of-function effect, which favours the survival of HCC cells. Thus, both inhibition of this effect by PRIMA-1 and removal of the mutant by siRNA can lead to the decrease of survival capacity of HCC cells.
Paz M, Ferretti G, Martins-Dinis M, Ferreira B, Faier-Pereira A, Barnoud T Front Mol Biosci. 2023; 10:1165132.
PMID: 37101558 PMC: 10123287. DOI: 10.3389/fmolb.2023.1165132.
Jiang B, Zhou X, Yang T, Wang L, Feng L, Wang Z Front Cardiovasc Med. 2023; 10:1088575.
PMID: 37063954 PMC: 10090687. DOI: 10.3389/fcvm.2023.1088575.
Anticancer Therapeutic Strategies Targeting p53 Aggregation.
Ferretti G, Quarti J, Dos Santos G, Rangel L, Silva J Int J Mol Sci. 2022; 23(19).
PMID: 36232329 PMC: 9569952. DOI: 10.3390/ijms231911023.
Menichini P, Monti P, Speciale A, Cutrona G, Matis S, Fais F Cells. 2021; 10(1).
PMID: 33430525 PMC: 7827888. DOI: 10.3390/cells10010098.
Cui J, Shen H, Lim L Pharmaceuticals (Basel). 2020; 13(12).
PMID: 33260729 PMC: 7760785. DOI: 10.3390/ph13120432.